Role of Molecular Markers in Endometrial Cancer: Review
- 11 Downloads
Genomic studies have given insights into the heterogeneity of endometrial cancer based on its molecular alterations. The unravelling of a four-tier molecular classification of endometrial cancer, that is biologically different, has challenged clinicians to take up a therapeutic approach incorporating this vital information. Embracing this novel classification in a clinical setting is not always practical. This review looks into pragmatic methods to ascertain the molecular subtypes and how this can be incorporated into the traditional clinicopathological parameters. Integrated risk stratification will become an essential component of care in gynaecologic oncology. Molecular characterisation furthers accords an opportunity to identify and screen family members affected by Lynch syndrome. This review summarises the key features of the molecular subtype-based classification in endometrial carcinoma and the results published from various patient cohorts and also discusses the potential application of this information in a clinical setting that will result in delivering a more objective and individualised patient care.
KeywordsEndometrial cancer Molecular marker The cancer genome atlas (TCGA) Mutation Diagnostic test
This work was supported by the Science and Engineering Research Board grant (SERB/F/10827/2017–2018 dated 17 March 2018) accorded to Dr. Santhosh Kuriakose for the project ‘Genetic profiling of Carcinoma Endometrium and Prognostic significance of mutations in POLE gene’ conducted at Multidisciplinary Research Unit (MRU), DHR-ICMR-supported central research laboratory at Govt Medical College, Kozhikode (GMCK), Kerala, India. Author would like to thank Dr. Sathi P.P., Professor, Department of Pathology, Dr. Dhanasooraj Dhananjayan, Research Scientist II and Ms. Shammy S, Research Scientist I, MRU, GMCK.
Compliance with ethical standards
Conflict of interest
The author has no conflicts of interest to disclose.
- 6.Garg K, Leitao M, Kauff N, Hansen J, Kosarin K, Shia J, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33(6):925–33.CrossRefGoogle Scholar
- 25.McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015;137(2):306–10.CrossRefGoogle Scholar
- 27.PORTEC-4a: molecular profile-based versus standard adjuvant radiotherapy in endometrial cancer—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03469674